Open AccessAssessment of TANK‐binding kinase 1 as a therapeutic target in cancer
Author(s) -
Cruz Victoria H.,
Brekken Rolf A.
Publication year - 2018
Publication title -
journal of cell communication and signaling
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 44
eISSN - 1873-961X
pISSN - 1873-9601
DOI - 10.1007/s12079-017-0438-y
Subject(s) - tank binding kinase 1 , effector , protein kinase b , innate immune system , kinase , carcinogenesis , cancer , cancer research , autophagy , oncogene , biology , signal transduction , medicine , immunology , immune system , microbiology and biotechnology , map kinase kinase kinase , cell cycle , biochemistry , genetics , apoptosis
TANK‐binding kinase 1 (TBK1) is central to multiple biological processes that promote tumorigenesis including cell division, autophagy, innate immune response and AKT‐pro survival signaling. TBK1 is well studied and most known for its function in innate immunity. However, the serine threonine protein kinase received significant attention as a synthetic lethal partner and effector of the major oncogene, RAS . This review summarizes newly identified cancer promoting functions of TBK1 and evaluates the therapeutic potential of targeting TBK1 in cancer.